Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Rating) has received an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company. The […]
Brokerages expect Dyne Therapeutics, Inc. (NYSE:DYN – Get Rating) to report earnings per share (EPS) of ($0.81) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Dyne Therapeutics’ earnings, with estimates ranging from ($0.88) to ($0.70). Dyne Therapeutics posted earnings per share of ($0.58) during the same quarter last year, which […]
Dyne Therapeutics (NASDAQ:DYN – Get Rating) and Sol-Gel Technologies (NASDAQ:SLGL – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations. Profitability This table compares Dyne Therapeutics and Sol-Gel Technologies’ […]